Imugene Limited

ASX (AUD): Imugene Limited (IMU)

Last Price

0.038

Today's Change

-0.001 (2.56%)

Day's Change

0.038 - 0.039

Trading Volume

11,101,427

Overview

Market Cap

282 Million

Shares Outstanding

7 Billion

Avg Volume

23,554,692

Avg Price (50 Days)

0.05

Avg Price (200 Days)

0.07

PE Ratio

-1.90

EPS

-0.02

Earnings Announcement

26-Feb-2025

Previous Close

0.04

Open

0.04

Day's Range

0.038 - 0.039

Year Range

0.035 - 0.13

Trading Volume

11,101,427

Price Change Highlight

1 Day Change

-2.56%

5 Day Change

-7.32%

1 Month Change

-22.45%

3 Month Change

-26.92%

6 Month Change

-45.71%

Ytd Change

-65.45%

1 Year Change

-58.24%

3 Year Change

-92.83%

5 Year Change

-26.92%

10 Year Change

283.45%

Max Change

-99.74%

News and Blogs

No result.

Company Profile

Sector: Healthcare - Healthcare

Industry: Biotechnology

Description:

Imugene Limited, a clinical stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumors in Australia. Its lead product is HER-Vaxx, a HER2-positive cancer vaccine that stimulates a polyclonal antibody response against HER2/neu receptors in gastric and breast cancer. The company's HER-Vaxx is in Phase 1b/2 study for gastric cancer. It also engages in developing PD1-Vaxx, a cancer vaccine that aims to induce the body to produce polyclonal antibodies that block PD-1 signalling; and CF33, a combination of genomic sequences from various vaccinia virus strains to generate potent virus. The company has a research collaboration with Celularity Inc. to develop the combination of Imugene's CD19 oncolytic virus technology and Celularity's CD19 targeting allogeneic chimeric antigen receptor T-cell therapy, CyCART-19 for the treatment of solid tumors; and has a strategic collaboration with Eureka Therapeutics, Inc. Imugene Limited was incorporated in 1986 and is based in Sydney, Australia.

Discussions
Be the first to like this. Showing 0 of 0 comments

Post a Comment